Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Study of 3 vs 6 Courses of Neoadjuvant Carboplatin-paclitaxel Chemotherapy in Stage IIIC or IV Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma

NCT02125513 is registered in ClinicalTrials.gov with IRCCS Azienda Ospedaliero-Universitaria di Bologna as lead sponsor.

NCT NCT02125513
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02125513 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Study of 3 vs 6 Courses of Neoadjuvant Carboplatin-paclitaxel Chemotherapy in Stage IIIC or IV Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma
Lead sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Phase
Phase 2
Overall status
Unknown status
Start date
January 31, 2014
Completion date
December 31, 2023
Enrollment
129 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube carcinoma, ovarian cancer, peritoneal carcinoma